Clinical and neurodevelopmental correlates of aggression in early psychosis.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
10 2019
Historique:
received: 02 11 2018
revised: 10 03 2019
accepted: 28 07 2019
pubmed: 8 8 2019
medline: 6 10 2020
entrez: 8 8 2019
Statut: ppublish

Résumé

Although mental illness accounts for only 4% of aggressive behavior in the general population, there remains a modest association between aggressive behavior and psychotic disorders, particularly in the early stages of the illness. However, little is known about the specific factors associated to this increased risk. The present study aims to assess the rates, characteristics and risk factors of aggressive behavior in first episode psychosis patients (FEP). We conducted a retrospective chart review of 449 FEP patients recruited from an outpatient early psychosis clinic. Aggressive behavior and clinical information were rated based upon information gathered from the chart review of data collected at baseline and after 6 months of follow-up. Rates of aggressive behavior were 54.3% in FEP patients. Aggressive behavior was significantly associated with higher rates of history of birth complications, neurodevelopmental delays, learning difficulties, alcohol use disorders, and the clinical domain of poverty symptoms. In addition to aggressive behavior, 16.7% of FEP patients exhibited suicidal ideation or behaviors and 11.4% exhibited non-suicidal self-injurious behavior (NSSIB). In contrast to baseline, aggressive behaviors at 6 months follow up were almost entirely absent. Patients at early stages of psychosis have high rates of aggressive and suicidal behavior prior to contact with clinical services. Neurodevelopmental adversities, alcohol use disorders and poverty symptoms are associated to higher risk of aggression in early psychosis. Participation in early psychosis specialty care resulted in a dramatic reduction in aggressive behavior.

Sections du résumé

BACKGROUND
Although mental illness accounts for only 4% of aggressive behavior in the general population, there remains a modest association between aggressive behavior and psychotic disorders, particularly in the early stages of the illness. However, little is known about the specific factors associated to this increased risk.
AIMS
The present study aims to assess the rates, characteristics and risk factors of aggressive behavior in first episode psychosis patients (FEP).
METHOD
We conducted a retrospective chart review of 449 FEP patients recruited from an outpatient early psychosis clinic. Aggressive behavior and clinical information were rated based upon information gathered from the chart review of data collected at baseline and after 6 months of follow-up.
RESULTS
Rates of aggressive behavior were 54.3% in FEP patients. Aggressive behavior was significantly associated with higher rates of history of birth complications, neurodevelopmental delays, learning difficulties, alcohol use disorders, and the clinical domain of poverty symptoms. In addition to aggressive behavior, 16.7% of FEP patients exhibited suicidal ideation or behaviors and 11.4% exhibited non-suicidal self-injurious behavior (NSSIB). In contrast to baseline, aggressive behaviors at 6 months follow up were almost entirely absent.
CONCLUSIONS
Patients at early stages of psychosis have high rates of aggressive and suicidal behavior prior to contact with clinical services. Neurodevelopmental adversities, alcohol use disorders and poverty symptoms are associated to higher risk of aggression in early psychosis. Participation in early psychosis specialty care resulted in a dramatic reduction in aggressive behavior.

Identifiants

pubmed: 31387826
pii: S0920-9964(19)30325-1
doi: 10.1016/j.schres.2019.07.045
pmc: PMC7259809
mid: NIHMS1579381
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

171-176

Subventions

Organisme : NICHD NIH HHS
ID : T32 HD091059
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Acta Psychiatr Scand. 2002 Mar;105(3):179-88
pubmed: 11939971
Am J Psychiatry. 2006 Mar;163(3):418-25
pubmed: 16513862
Br J Psychiatry. 1992 Oct;161:501-5
pubmed: 1393336
PLoS Med. 2009 Aug;6(8):e1000120
pubmed: 19668362
Br J Psychiatry. 1997 Jul;171:9-14
pubmed: 9328487
Res Dev Disabil. 2014 Dec;35(12):3496-507
pubmed: 25213474
Acta Psychiatr Scand. 2013 Apr;127(4):255-68
pubmed: 23289890
Hosp Community Psychiatry. 1990 Jul;41(7):761-70
pubmed: 2142118
J Abnorm Psychol. 2003 Feb;112(1):132-43
pubmed: 12653421
Am J Psychiatry. 1986 Jan;143(1):35-9
pubmed: 3942284
Acta Psychiatr Scand. 2013 Jun;127(6):442-54
pubmed: 23298325
Am J Psychiatry. 2002 Jul;159(7):1080-92
pubmed: 12091183
Bipolar Disord. 2012 May;14(3):283-90
pubmed: 22548901
Am J Psychiatry. 2011 Dec;168(12):1266-77
pubmed: 22193671
J Clin Exp Neuropsychol. 2006 Feb;28(2):270-82
pubmed: 16484098
Schizophr Res. 2017 Oct;188:13-20
pubmed: 28131598
Eur Psychiatry. 2017 Feb;40:65-75
pubmed: 27992836
Int J Clin Pract. 2014 Mar;68(3):330-5
pubmed: 24471741
Arch Gen Psychiatry. 2000 Oct;57(10):979-86
pubmed: 11015816
BMC Psychiatry. 2013 Oct 09;13:255
pubmed: 24106884
J Nerv Ment Dis. 1988 Sep;176(9):539-46
pubmed: 3418327
Acta Psychiatr Scand. 2013 Dec;128(6):413-21
pubmed: 23521361
Arch Gen Psychiatry. 2009 Feb;66(2):152-61
pubmed: 19188537
Eur Neuropsychopharmacol. 2015 Dec;25(12):2278-88
pubmed: 26475577
Arch Gen Psychiatry. 2011 Oct;68(10):1058-64
pubmed: 21969462
Arch Gen Psychiatry. 2006 May;63(5):490-9
pubmed: 16651506
Schizophr Bull. 2011 Sep;37(5):913-20
pubmed: 21860037
Lancet. 1994 Nov 19;344(8934):1398-402
pubmed: 7968076
Neurobiol Dis. 2013 May;53:3-9
pubmed: 23123588
J Child Psychol Psychiatry. 2005 May;46(5):524-32
pubmed: 15845132
Soc Psychiatry Psychiatr Epidemiol. 2012 Nov;47(11):1795-806
pubmed: 22349207
Arch Gen Psychiatry. 1985 Jul;42(7):696-702
pubmed: 4015311
Schizophr Res. 2011 Feb;125(2-3):209-20
pubmed: 21208783
Br J Psychiatry. 1998 Mar;172:218-26
pubmed: 9614470

Auteurs

Pilar Lopez-Garcia (P)

Department of Psychiatry, Universidad Autonoma de Madrid, CIBERSAM, Madrid, Spain. Electronic address: p.lopez@uam.es.

Stefania Ashby (S)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Pooja Patel (P)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Katherine M Pierce (KM)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Monet Meyer (M)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Adi Rosenthal (A)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Madison Titone (M)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Cameron Carter (C)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America; Center for Neuroscience, University of California-Davis, Davis, CA, United States of America.

Tara Niendam (T)

Department of Psychiatry & Behavioral Sciences, University of California-Davis, Sacramento, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH